CAS 156251-01-3

H-GLU-ALA-ALA-GLY-ILE-GLY-ILE-LEU-THR-VAL-OH

Descripción:

La sustancia química con el nombre "H-GLU-ALA-ALA-GLY-ILE-GLY-ILE-LEU-THR-VAL-OH" y el número CAS "156251-01-3" es un péptido compuesto por una secuencia de aminoácidos. Este péptido presenta una combinación de residuos hidrofílicos e hidrofóbicos, lo que puede influir en su solubilidad e interacción con membranas biológicas. La presencia de ácido glutámico (GLU) introduce una cadena lateral cargada negativamente, mientras que los aminoácidos de cadena ramificada como la isoleucina (ILE) y la leucina (LEU) contribuyen a su carácter hidrofóbico. El grupo hidroxilo terminal (OH) sugiere que puede tener algunas características polares, lo que podría mejorar su solubilidad en entornos acuosos. Péptidos como este pueden desempeñar roles significativos en procesos biológicos, incluyendo señalización, actividad enzimática y funciones estructurales en proteínas. La secuencia y composición específicas también pueden afectar su actividad biológica, estabilidad y posibles aplicaciones en farmacéutica o biotecnología. Comprender las propiedades de tales péptidos es crucial para su utilización en contextos de investigación y terapéuticos.

Fórmula: C₄₂H₇₄N₁₀O₁₄

Sinónimos:

• Glu-Ala-Ala-Gly-Ile-Gly-Ile-Leu-Thr-Val
• Eaagigiltv
• Antigen Sk29-Aa (26-35) (Human)
• Antigen Lb39-Aa (26-35) (Human)
• Mart 1 (26-35)
• Mart-1 (26-35) (Human)
• Melanoma Antigen Recognized By T-Cells 1 (26-35) (Human)

MART-1 (26-35) (human)

CAS: 156251-01-3

MART-1 (26-35) has been shown to be better recognized by a number of polyclonal and monoclonal populations of tumor-reactive HLA-A*0201-restricted cytotoxic T lymphocytes (CTL) than MART-1 (27-35) (human).

Fórmula: C₄₂H₇₄N₁₀O₁₄

Pureza: 96.7%

Forma y color: White

Peso molecular: 943.11

Ref: 01-4027904

MART-1 (26-35) (human)

CAS: 156251-01-3

MART-1 (26-35) (human)

Pureza: ≥98%

Peso molecular: 943.1g/mol

Ref: 54-BUP21017

MART-1 (26-35) (human)

CAS: 156251-01-3

MART-1 (26-35) (human) (MART-1 (26-35) human) is a peptide fragment of MART-1 protein.

Fórmula: C₄₂H₇₄N₁₀O₁₄

Pureza: >99.99%

Forma y color: Solid

Peso molecular: 943.1

Ref: TM-T7489

MART-1 (26-35)

CAS: 156251-01-3

Native Melan-A (26-35) decapeptide derives from the melanocyte lineage-specific protein Melan-A/MART-1, which is expressed in almost 75-100% of primary and metastatic melanomas.
The region 26-35 of Melan-A protein acts as an antigenic peptide that is recognized by CD8+ tumor-reactive cytolytic T lymphocytes (CTLs) for designing antigen-specific cancer vaccines1. It has been shown that CD8+ Melan-A-specific CTLs isolated from melanoma patients efficiently lyse the Melan-A-expressing HLA-A*0201+ melanoma cell line. However, CTLs preferentially recognize the Melan-A (26-35) peptide as compared with the Melan-A (27-35) peptide. Moreover, the Melan-A (26-35) A27L analog (ELAGIGILTV) has a higher binding affinity to HLA-A*0201 than the native Melan-A (26-35) peptide (EAAGIGILTV), and consequently displays more potent antigenicity and immunogenicity.
It has been reported that the concentration of Melan-A (26-35) A27L analog required to obtain 50% of maximal antigenic activity (EC50) is 0.01nM, whereas that of the native Melan-A (26-35) peptide is 0.25nM1. Therefore, the relative activity of Melan-A (26-35) A27L analog is 25 fold higher than that of the native Melan-A (26-35) peptide.
Furthermore, functional competition assay has shown that the concentration of Melan-A (26-35) A27L analog required to achieve 50% inhibition (IC50) of tumor lysis is 2nM, which is 10 fold lower than that of the native Melan-A (26-35) peptide. Regarding peptide stability in human serum, the half-lifes (t1/2) of the native Melan-A (26-35) peptide and the A27L analog are quite similar (45 and 40min, respectively) as measured by HPLC-ESI-MS, but much higher than that of the Melan-A (27-35) nonapeptide (5min).

Fórmula: C₄₂H₇₄N₁₀O₁₄

Forma y color: Powder

Peso molecular: 943.1 g/mol

Ref: 3D-CRB1001607

MART-1 (26-35) (human)

CAS: 156251-01-3

Native Melan-A (26-35) decapeptide derives from the melanocyte lineage-specific protein Melan-A/MART-1, which is expressed in almost 75-100% of primary and metastatic melanomas. The region 26-35 of Melan-A protein acts as an antigenic peptide that is recognized by CD8+ tumor-reactive cytolytic T lymphocytes (CTLs) for designing antigen-specific cancer vaccines1. It has been shown that CD8+ Melan-A-specific CTLs isolated from melanoma patients efficiently lyse the Melan-A-expressing HLA-A*0201+ melanoma cell line. However, CTLs preferentially recognize the Melan-A (26-35) peptide as compared with the Melan-A (27-35) peptide. Moreover, the Melan-A (26-35) A27L analog (ELAGIGILTV) has a higher binding affinity to HLA-A*0201 than the native Melan-A (26-35) peptide (EAAGIGILTV), and consequently displays more potent antigenicity and immunogenicity. It has been reported that the concentration of Melan-A (26-35) A27L analog required to obtain 50% of maximal antigenic activity (EC50) is 0.01nM, whereas that of the native Melan-A (26-35) peptide is 0.25nM1. Therefore, the relative activity of Melan-A (26-35) A27L analog is 25 fold higher than that of the native Melan-A (26-35) peptide. Furthermore, functional competition assay has shown that the concentration of Melan-A (26-35) A27L analog required to achieve 50% inhibition (IC50) of tumor lysis is 2nM, which is 10 fold lower than that of the native Melan-A (26-35) peptide. Regarding peptide stability in human serum, the half-lifes (t1/2) of the native Melan-A (26-35) peptide and the A27L analog are quite similar (45 and 40min, respectively) as measured by HPLC-ESI-MS, but much higher than that of the Melan-A (27-35) nonapeptide (5min).

Fórmula: C₄₂H₇₄N₁₀O₁₄

Peso molecular: 943.11 g/mol

Ref: 3D-PP50002

MART-1 (26-35) (human) trifluoroacetate salt

CAS: 156251-01-3

Native Melan-A (26-35) decapeptide derives from the melanocyte lineage-specific protein Melan-A/MART-1, which is expressed in almost 75-100% of primary and metastatic melanomas.
The region 26-35 of Melan-A protein acts as an antigenic peptide that is recognized by CD8+ tumor-reactive cytolytic T lymphocytes (CTLs) for designing antigen-specific cancer vaccines1. It has been shown that CD8+ Melan-A-specific CTLs isolated from melanoma patients efficiently lyse the Melan-A-expressing HLA-A*0201+ melanoma cell line. However, CTLs preferentially recognize the Melan-A (26-35) peptide as compared with the Melan-A (27-35) peptide. Moreover, the Melan-A (26-35) A27L analog (ELAGIGILTV) has a higher binding affinity to HLA-A*0201 than the native Melan-A (26-35) peptide (EAAGIGILTV), and consequently displays more potent antigenicity and immunogenicity.
It has been reported that the concentration of Melan-A (26-35) A27L analog required to obtain 50% of maximal antigenic activity (EC50) is 0.01nM, whereas that of the native Melan-A (26-35) peptide is 0.25nM1. Therefore, the relative activity of Melan-A (26-35) A27L analog is 25 fold higher than that of the native Melan-A (26-35) peptide.
Furthermore, functional competition assay has shown that the concentration of Melan-A (26-35) A27L analog required to achieve 50% inhibition (IC50) of tumor lysis is 2nM, which is 10 fold lower than that of the native Melan-A (26-35) peptide. Regarding peptide stability in human serum, the half-lifes (t1/2) of the native Melan-A (26-35) peptide and the A27L analog are quite similar (45 and 40min, respectively) as measured by HPLC-ESI-MS, but much higher than that of the Melan-A (27-35) nonapeptide (5min).

Fórmula: C₄₂H₇₄N₁₀O₁₄

Pureza: Min. 95%

Peso molecular: 943.1 g/mol

Ref: 3D-FM109182